Mundipharma demonstrates superiority of non-opioid Penthrox in relieving pain

Pharmaceutical Technology | October 16, 2019

At the European Society of Emergency Medicine Congress, UK-based Mundipharma announced positive results from various trials of its analgesic Penthrox (methoxyflurane) for pain relief. Carried out in Italy, the MEDITA study demonstrated Penthrox was superior to standard analgesic treatment (SAT) – IV morphine for severe pain and IV paracetamol or ketoprofen for moderate trauma pain – in terms of change in pain intensity over ten minutes, the primary endpoint. Penthrox was also rated as excellent, very good or good by significantly more patients and healthcare professionals than the SAT option. With 72.7% of patients giving one of these positive ratings for Penthrox, compared to 60.9% for the SAT group; while 90.3% of healthcare professionals gave Pethrox a positive rating, compared to 64.4% for the control group. In the placebo-controlled PenASAP study, which was conducted in France, Penthrox combined with the standard of care group experienced a median time of 35 minutes to pain relief, whereas placebo plus standard of care did not reach the definition of pain relief on the visual analogue scale.

Spotlight

Is solid form characterization critical in your line of work, but you lack expertise in X-ray diffraction (XRD)? Do you need an efficient tool to support you with lead optimization? Do you need an easy way to validate the stability of your solid form following processing?

Spotlight

Is solid form characterization critical in your line of work, but you lack expertise in X-ray diffraction (XRD)? Do you need an efficient tool to support you with lead optimization? Do you need an easy way to validate the stability of your solid form following processing?

Related News

Pharmacy Market

TailorMed Joins Forces with TwelveStone Health Partners to Improve Medication Access and Affordability

Businesswire | August 24, 2023

TailorMed, a leading technology company offering the nation’s largest network of patients, providers, pharmacies, life science companies, and other partners dedicated to improving healthcare affordability, today announced it is collaborating with TwelveStone Health Partners. TwelveStone, which provides comprehensive chronic care medication services, has confidently invested in TailorMed’s best-in-class solutions to remove financial barriers for patients with high-cost conditions. The cost of specialty drugs, including infused therapies, is rising rapidly. In fact, the average annual cost for one specialty medication is estimated to be at least $84,000. These staggering expenses often lead to medication nonadherence and prescription abandonment. Financial assistance programs help eligible patients pay for treatment, yet these resources remain underutilized. TailorMed offers a comprehensive solution by empowering providers and pharmacies to proactively flag patients in need. The technology then matches patients with relevant funding opportunities, drawing on more than 6,000 resources ranging from drug manufacturer copay assistance to foundation grants. TwelveStone Health Partners will use the company’s enterprise platform to improve access to critical therapies for patients who could not otherwise afford them. “This partnership enhances our commitment to expanding patient access and addressing affordability to ensure that those who need them most can receive innovative medications in a warm, caring, patient-centric care environment,” said Shane Reeves, chief executive officer, TwelveStone Health Partners. “TailorMed’s technology provides real value to our patients who deserve a higher level of care and support.” The process of connecting patients with financial assistance has historically been an arduous and highly manual process. The TailorMed platform will significantly reduce the administrative burden for TwelveStone Health Partners, allowing staff to efficiently address patients’ financial needs. The company’s Pharmacy solution will also enable staff to streamline the management and tracking of free and replacement drug orders. “We’re very proud to collaborate with leading specialty pharmacies and infusion centers such as TwelveStone Health Partners as our network continues to expand,” said Bryan Bloom, head of enterprise sales at TailorMed. “By leveraging our solutions to tackle affordability, TwelveStone will be better equipped to provide superior patient experiences, while ensuring no one falls through the cracks due to costs.” Srulik Dvorsky, co-founder and chief executive officer at TailorMed, also shared: “We are especially pleased to add TwelveStone Health Partners to our growing list of infusion center clients. As a company committed to innovating at scale, we want to do everything we can to ensure our partners can also deliver care at scale.” About TailorMed TailorMed offers the nation’s largest network of patients, providers, pharmacies, partners, and life science companies focused on ensuring all patients across all medical conditions can afford treatment. Driven by TailorMed's best-in-class platform, network constituents can proactively identify, match, and enroll patients in financial assistance programs to deliver a world-class patient financial experience while reducing the cost of care delivery and increasing revenues. TailorMed’s secure, web-based financial assistance solutions are deployed across more than 1,000 sites of care, including Providence Health, UnityPoint Health, Yale-New Haven Health, and Advocate Aurora Health. About TwelveStone Health Partners TwelveStone Health Partners incorporates the objective of glorifying God into its mission by delivering a higher level of service to partners and patients. As an organization, TwelveStone supports the transition from acute to post-acute care environments and the transition from sickness to health. Founded in 2016 TwelveStone is the third iteration of pharmacy organizations founded by Shane Reeves and the Reeves family. Today TwelveStone is rapidly expanding across the Southeast anchored by spa-like infusion centers conveniently located in suburban communities supported by additional services including package medications, home infusion, enteral and injections. TwelveStone is dedicated to providing the highest level of care to those with chronic, complex conditions in the environment that is most convenient for both the patient and their loved ones.

Read More

Pharmacy Market

Cytel Acquires French Group stève consultants to Further Expand Value Evidence and Real-World Analytics Capabilities

Businesswire | July 07, 2023

Cytel Inc., provider of quantitative insights and health data analytics to leaders in life sciences, has acquired stève consultants, specialists in market access, real-world (RWE), and health economics and outcomes research (HEOR). The acquisition further expands Cytel’s real-world & advanced analytics (RWAA) capabilities, giving sponsors an expanded global offering, with access to additional specialists and localized expertise. This acquisition continues the company’s growth in key European markets, following the recent acquisition of Nordic regulatory affairs and RWE experts SDS Life Science. Cytel now stands as one of the largest global providers of HEOR, RWE, global value strategy and market access consulting. Achieving favorable market access is crucial in today’s highly competitive clinical development environment. But doing so is challenging and requires access to deep region-specific expertise. Cytel has long excelled at using proven quantitative techniques to transform real-world data into actionable insights to help sponsors successfully tap into new markets. The acquisition of stève consultants continues this journey, augmenting and extending the localized market access, product launch, and regulatory support it can offer in France, a critical European market. "stève consultants have crafted a team of unparalleled know-how in regional market access, HEOR, and RWE,” said Radek Wasiak, General Manager, Real-World and Advanced Analytics (RWAA), Cytel. “We look forward to welcoming them to Cytel as together we can now provide an exceptional service at the local level in France but also plug into the global dossier needs of our clients. For sponsors, this means a more global strategic offering, deeper connectivity to world-class expertise in France, and greater product launch success.” stève consultants has spent 17 years optimizing the value of its customers’ healthcare products for the French market, with deep expertise in market access, HEOR, and RWE. stève consultants is a leader in market access and one of the largest and most accomplished RWE services providers in France. “Joining forces with Cytel further expands the insight and support we can offer for market access and market maintenance in France,” said Stève Bénard, Executive Manager, stève consultants. “Both companies share a pioneering spirit, long-held market reputations for scientific rigor, and an excellent client service ethos. We’re proud to play a critical role in augmenting the way sponsors tap into markets and transform patients’ lives.” The transaction was closed on June 30, 2023. Terms were not disclosed. About Cytel Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution. For over thirty-five years, Cytel’s scientific rigor and operational excellence have enabled biotech and pharmaceutical companies to navigate uncertainty, prove value and make confident, evidence-based decisions. Its experts deliver industry-leading software, data-driven analytics, real-world evidence and strategic consulting. Headquartered in Waltham, Massachusetts, Cytel has more than 2,000 employees across North America, Europe and Asia. About stève consultants stève consultants, founded in 2006, is a consulting and research company specializing in optimizing the value of healthcare products on the French market. stève consultants supports its biotech and pharmaceutical clients in the development and the implementation of their regional market access strategy, including the implementation of early access programs, the demonstration of health-economic value, the generation of real-life data and the writing of HTA dossiers. stève consultants is a leader in market access, and one of the most accomplished RWE service providers in France. stève consultants has extensive experience and works on the latest therapeutic innovations.

Read More

Pharmacy Market

Frontage Acquires Nucro-Technics Inc. and Nucro-Technics Holdings, Inc.

PRNewswire | August 17, 2023

Frontage Laboratories, Inc. and its wholly-owned subsidiary, Frontage Canada, Inc., completed the acquisition of Nucro-Technics Inc. and its affiliate Nucro-Technics Holdings, Inc. Nucro-Technics is a pharmaceutical contract research organization that conducts analytical chemistry, microbiology, toxicology, bioanalytical, and stability sample storage and testing services. In addition, it provides consulting services, especially in quality control and assurance as well as in Natural Health Product Regulations. Nucro-Technics, located in the Toronto, Canada metropolitan area, operates in a state-of-the-art 60,000 square foot facility and employs personnel having expertise in testing both large and small molecules designed to treat various medical conditions. For over 50 years, Nucro-Technics has been conducting studies for various clients including major pharmaceutical, biotech, and medical device companies, as well as smaller organizations including industry trade groups and academia. Nucro-Technics has successfully developed and validated numerous methods, as well as participated in providing comprehensive IND packages to clients for regulatory submissions. Nucro-Technics, an ISO 9001:2015 certified organization, conducts studies that are in compliance with GLP and GMP regulations. "Today marks a momentous and an exciting occasion. It is a day to celebrate two great companies coming together. It is with great pleasure that I welcome the extraordinary Nucro-Technics team to the Frontage family," said Dr. Abdul Mutlib, CEO of Frontage. "Nucro-Technics has been recognized as a leader in the Canadian CRO market for over 50 years, and its unparalleled client services is a perfect match for the culture of Frontage Laboratories. This acquisition not only significantly strengthens our presence in Canada, but also will enable the combined organization to offer a more expansive suite of services to clients across the globe. We are looking forward to partnering with the Nucro team to deliver the world-class expertise that clients have come to expect from us." According to Dr. Song Li, Founder and Chairman of Frontage: "Nucro has developed a remarkable platform with a truly impressive team of experts. The closing of this transaction marks the next step in our ongoing effort to build Frontage into one of the major players in the global CRO market. In doing so, we will continue our focus on delivering the highest levels of quality, technology and expertise to our clients." "I'm delighted to announce that we will be partnering with Frontage Labs for the next phase of Nucro Technics' growth journey. Since founding the business in 1970, we've worked hard to become the North American boutique in pre-clinical and drug product release testing services. Partnering with Frontage Labs marks an exciting chapter in the evolution of our efforts to support and accelerate pharmaceutical research and development," said John Fanaras of Nucro Technics. Frontage was advised by Borden Ladner Gervais LLP (BLG) while Nucro-Technics was advised by Dentons and PricewaterhouseCoopers Corporate Finance Inc. About Frontage Frontage Holdings Corp (1521.HK), together with its wholly owned subsidiary Frontage Laboratories, Inc., is a global Contract Research Organization (CRO) which provides integrated, science-driven, product development services from drug discovery to late phase clinical process to enable biopharmaceutical companies to achieve their development goals.  Comprehensive services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment and early phase clinical studies. Frontage has enabled many biotechnology companies and leading pharmaceutical companies of varying sizes to advance a myriad of new molecules through development and to successfully file global regulatory submissions.

Read More